Banca de DEFESA: ANA BEATRIZ SILVA DE OLIVEIRA

Uma banca de DEFESA de MESTRADO foi cadastrada pelo programa.
STUDENT : ANA BEATRIZ SILVA DE OLIVEIRA
DATE: 31/07/2024
TIME: 08:00
LOCAL: Auditório do Departamento de Química
TITLE:

SYNTHETIC STRATEGIES FOR OBTAINING PLATINUM(2+)-BASED ANTINEOPLASTIC METALOPHARMACEUTICALS

KEY WORDS:

Cancer, platinum complexes, chemotherapy, aminoalcohol.

PAGES: 62
BIG AREA: Ciências Exatas e da Terra
AREA: Química
SUBÁREA: Química Inorgânica
SPECIALTY: Química Bio-Inorgânica
SUMMARY:

Data from the World Health Organization (WHO) show that cancer is the second leading cause of death worldwide and that there were 19.3 million cases of cancer in the world in 2020, with an estimated 30.2 million cases by 2040. One of the primary cancer treatments is chemotherapy, which involves the administration of chemical compounds, organic or inorganic, to interfere with the process of cell proliferation or cause cell death. The use of platinum complexes as chemotherapeutic agents has been used since 1960, with the discovery of the antitumor activity of cisplatin. However, chemotherapy has limited efficacy due to the severe side effects caused by platinum compounds, as well as resistance to these drugs, a phenomenon known as MDR (multidrug resistance). This work aims to synthesize, characterize, and evaluate the antitumor activity of new platinum complexes with amino alcohol ligands. These new complexes were obtained in three stages: the first involved recovering platinum from laboratory waste and obtaining the precursor K2[PtCl4]. In the second stage, the amino alcohol ligands IM-AB and AM-AB were synthesized and characterized using infrared and electronic absorption spectroscopy. Finally, the third stage involved the synthesis of the platinum complexes Pt(IM-AB) and Pt(AM-AB) from K2[PtCl4] with the amino alcohol ligands. The complexes were characterized using infrared spectroscopy, electronic absorption spectroscopy, and 13C NMR. For the biological tests (in vitro test), cells from the HL-60 cancer lineage (human promyelocytic leukemia), MCF-7 (human breast cancer), and the RAW 264.7 non-cancerous lineage (murine macrophage) were used. The compounds showed no cytotoxicity for RAW 264.7, and the Pt(IM-AB) compound showed cytotoxicity at the concentrations tested for the HL-60 lineage, with an IC50 of 13.79.

COMMITTEE MEMBERS:
Externa à Instituição - AMANDA KATIELLY JORDÃO PESSOA FELIX DA SILVA
Interno - JOAO RUFINO DE FREITAS FILHO
Presidente - MONICA FREIRE BELIAN